| Literature DB >> 35560964 |
Olesia Korsun1,2, Hanna Renvall1,2, Jussi Nurminen1,3, Jyrki P Mäkelä1, Eero Pekkonen4.
Abstract
Despite optimal oral drug treatment, about 90% of patients with Parkinson's disease develop motor fluctuation and dyskinesia within 5-10 years from the diagnosis. Moreover, the patients show non-motor symptoms in different sensory domains. Bilateral deep brain stimulation (DBS) applied to the subthalamic nucleus is considered the most effective treatment in advanced Parkinson's disease, and it has been suggested to affect sensorimotor modulation and relate to motor improvement in patients. However, observations on the relationship between sensorimotor activity and clinical improvement have remained sparse. Here, we studied the somatosensory evoked magnetic fields in 13 right-handed patients with advanced Parkinson's disease before and 7 months after stimulator implantation. Somatosensory processing was addressed with magnetoencephalography during alternated median nerve stimulation at both wrists. The strengths and the latencies of the ~60-ms responses at the contralateral primary somatosensory cortices were highly variable but detectable and reliably localized in all patients. The response strengths did not differ between preoperative and postoperative DBSON measurements. The change in the response strength between preoperative and postoperative condition in the dominant left hemisphere of our right-handed patients correlated with the alleviation of their motor symptoms (p = .04). However, the result did not survive correction for multiple comparisons. Magnetoencephalography appears an effective tool to explore non-motor effects in patients with Parkinson's disease, and it may help in understanding the neurophysiological basis of DBS. However, the high interindividual variability in the somatosensory responses and poor tolerability of DBSOFF condition warrants larger patient groups and measurements also in non-medicated patients.Entities:
Keywords: Parkinson's disease; deep brain stimulation; magnetoencephalography; non-motor cerebral activity; somatosensory processing
Mesh:
Year: 2022 PMID: 35560964 PMCID: PMC9544049 DOI: 10.1111/ejn.15692
Source DB: PubMed Journal: Eur J Neurosci ISSN: 0953-816X Impact factor: 3.698
Clinical details of patients and their DBS parameters
| № | Sex, DBS op (age) | Handedness | PD duration before op (yr) | MEG measurements | Levodopa equivalent daily dose (LEDD, mg) | UPDRS III total scale (medication on) | DBS settings (left/right) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before DBS op (mo) | After DBS op (mo) | PRE | DBSON | PRE | DBSON | Voltage (V) | Type (bi‐ or monopolar) | Freq (Hz) | Pulse width (μs) | ||||
| 1 | F, 63 | R | 24 | 5 | 7 | 960 | 760 | 32 | 35 | 3.6/1.6 | Bi/bi | 160 | 60/60 |
| 2 | M, 57 | R | 15 | 11 | 6 | 1,618 | 1,310 | 32 | 21 | 2.5/2.5 | Mono/bi | 130 | 60/60 |
| 3 | M, 63 | R | 8 | 3 | 7 | 925 | 639 | 37 | 29 | 2.5/2.5 | Mono/mono | 160 | 60/60 |
| 4 | M, 62 | R | 17 | 8 | 5 | 1,408 | 1,407 | 37 | 33 | 3.6/3.1 | Mono/mono | 130 | 60/60 |
| 5 | M, 42 | R | 9 | 3 | 6 | 765 | 1,497 | 62 | 32 | 3.2/3.2 | Mono/mono | 130 | 60/60 |
| 6 | M, 49 | R | 14 | 8 | 11 | 1,263 | 1,105 | 51 | 24 | 3.5/3.1 | Bi/mono | 150 | 60/60 |
| 7 | M, 42 | R | 6 | 5 | 6 | 1,338 | 1,360 | 44 | 20 | 3.5/2.0 | Mono/mono | 130 | 60/60 |
| 8 | M, 62 | R | 18 | 4 | 7 | 1,158 | 560 | 27 | 20 | 2.9/3.0 | Mono/mono | 130 | 60/60 |
| 9 | F, 63 | R | 14 | 9 | 7 | 658 | 366 | 23 | 16 | 2.8/2.9 | Mono/mono | 130 | 60/60 |
| 10 | F, 56 | R | 18 | 0.5 | 7 | 1,562 | 1,386 | 74 | 34 | 2.6/2.7 | Mono/mono | 130 | 60/60 |
| 11 | M, 67 | R | 9 | 5 | 7 | 1,679 | 480 | 46 | 25 | 2.6/2.9 | Mono/mono | 150 | 120/60 |
| 12 | M, 45 | R | 9 | 5 | 5 | 1,481 | 1,255 | 31 | 29 | 3.5/3.8 | Bi/mono | 130 | 60/60 |
| 13 | M, 47 | R | 8 | 3 | 6 | 655 | 580 | 37 | 24 | 2.3/2.5 | Mono/mono | 180 | 60/60 |
Abbreviations: DBS, deep brain stimulation; DBSON, deep brain stimulation on; F, female; Freq., frequency; LEDD, levodopa equivalent daily dose; M, male; mo, months; op, DBS operation; PD, Parkinson's disease; PRE, preoperative condition; UPDRS III scale, Unified Parkinson's Disease Rating Scale; yr, years.
To calculate the levodopa equivalent daily dose (LEDD), the following formula was used: 100 mg l‐dopa = 130 mg contolled‐release l‐dopa = 70 mg l‐dopa + COMT inhibitor = 1 mg pramipexole = 5 mg ropinirole = 4 mg rotigotine.
FIGURE 1Somatosensory responses induced by the right‐sided median nerve (MN) stimulation in one patient. Top: Sensor‐level data; the insert depicts the left hemisphere channels with maximum response amplitude and the single‐trial responses at one channel (red = mean over 166 single‐trial responses, blue = ±1 SD). Bottom: The equivalent current dipole (ECD) location and orientation superimposed on the patient's magnetic resonance (MR) image (left) and strength of the ECD as a function of time (black = PRE, red = DBSON). Note: The stimulus artefacts are present at the 0‐ms time point
SI source strengths (mean ± SEM)
| Condition | Source strengths (nAm) | |
|---|---|---|
| Left hemisphere | Right hemisphere | |
| PRE ( | 46 ± 8 | 52 ± 8 |
| DBSON ( | 36 ± 7 | 52 ± 9 |
| DBSOFF ( | 35 ± 8 | 49 ± 10 |
The peak strength of the filtered response.
Abbreviations: DBSOFF, deep brain stimulation off; DBSON, deep brain stimulation on; LH, left hemisphere; PRE, preoperative condition; RH, right hemisphere.
FIGURE 2Scatter plot of the relative change of SI source strength between preoperative and DBSON condition and relative change of Unified Parkinson's Disease Rating Scale (UPDRS III) total motor score (r s[13] = −.58, p = .04)